Global Opioid Induced Constipation Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 2.69 Billion |
 Market Size (Forecast Year) |
USD 4.52 Billion |
 CAGR |
% |
| Major Markets Players |
>全球阿片类药物诱发的便秘药物市场，按活性成分（纳洛酮、鲁比前列酮、甲基纳曲酮溴化物、多库酯钠等）、治疗（非处方药、处方药和自然疗法）、给药方式（口服、肠胃外和其他）、最终用户（医院、家庭护理、专科中心和其他）、分销渠道（医院药房、网上药房和零售药房）划分 - 行业趋势和预测到 2031 年。
阿片类便秘药物市场分析及规模
根据美国国家生物技术信息中心发布的报告，慢性疼痛的特征是持续三个月或更长时间的持续不适，影响着约 10% 至 15% 的人口。在患有慢性非癌症疼痛的个体中，阿片类药物引起的便秘的患病率为 41% 至 81%。
2023 年全球阿片类药物引起的便秘药物市场规模价值 26.9 亿美元，预计到 2031 年将达到 45.2 亿美元，2024 年至 2031 年预测期内的复合年增长率为 6.7%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022（可定制为 2016 - 2021） |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
活性成分（纳洛昔康、鲁比前列酮、甲基纳曲酮溴化物、多库酯钠等）、治疗（非处方药、处方药和自然疗法）、给药方式（口服、肠胃外和其他）、最终用户（医院、家庭护理、专科中心和其他）、分销渠道（医院药房、网上药房和零售药房） |
|
覆盖国家 |
美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
辉瑞公司（美国）、罗氏公司（瑞士）、迈兰公司（美国）、费森尤斯卡比公司（德国）、Hikma Pharmaceuticals PLC（英国）、诺华公司（瑞士）、梯瓦制药工业有限公司（以色列）、百时美施贵宝公司（美国）、葛兰素史克公司（英国）、拜耳公司（德国）、阿拉宾度制药公司（印度）、SLA Pharma AG（英国）、Salix Pharmaceuticals（美国）、武田制药有限公司（日本）、雅培公司（美国）、勃林格殷格翰国际有限公司（德国）、默克公司（美国）、大熊制药公司（韩国）和 Cosmo Pharmaceuticals（爱尔兰） |
|
市场机会 |
|
市场定义
阿片类药物引起的便秘药物是专门用于缓解因使用阿片类止痛药引起的便秘的药物。这些药物通过靶向受阿片类药物影响的胃肠道受体起作用，帮助恢复正常的肠道功能并缓解便秘，而不会干扰阿片类药物的止痛效果。它们是因阿片类药物治疗而出现便秘副作用的患者的疼痛管理策略的重要组成部分。
阿片类便秘药物市场动态
驱动程序
- 阿片类药物使用率不断上升
用于缓解疼痛的阿片类药物处方的增加显著增加了全球阿片类药物引起的便秘 (OIC) 的发病率。阿片类药物通常用于治疗慢性疼痛，例如癌症相关疼痛或严重损伤，导致越来越多的人患有 OIC。因此，对有效的 OIC 药物的需求越来越大，以控制阿片类药物治疗的这种常见副作用并改善患者的生活质量，这是推动市场增长的主要因素。
- 加速药品审批举措
监管机构已实施计划，以加快新型阿片类便秘 (OIC) 药物的审批流程。这些举措旨在通过减少药物开发和审批所需的时间和资源来满足对有效治疗的迫切需求。简化监管流程有助于制药公司更快地将新型 OIC 药物推向市场，让患者更快地获得创新治疗。这种加速审批途径极大地促进了 OIC 药物市场的扩张。
- 药物输送技术的进步
Continuous innovations in drug delivery technology are driving the development of more effective and patient-friendly opioid-induced constipation (OIC) drugs. Novel delivery systems, such as controlled-release formulations and targeted drug delivery mechanisms, are designed to optimize OIC drugs' therapeutic effects while minimizing adverse effects like constipation. These advancements improve patient compliance and satisfaction and enhance the overall efficacy and safety profiles of OIC medications. Consequently, the evolution of drug delivery technology acts as a significant driver for the market's growth, fostering innovation and market expansion.
Opportunities
- Expanding Geriatric Population
As the global population ages, there is a notable increase in the number of elderly individuals who require opioid therapy for chronic pain management. This demographic is more susceptible to opioid-induced constipation (OIC) due to age-related changes in gastrointestinal function. Addressing the specific requirements of older population such as dosage adjustments and personalized treatment plans can create new opportunities for market growth.
- Personalized OIC Treatments
Tailored OIC therapies can address specific patient needs, potentially reducing side effects and improving treatment efficacy. This patient-centered approach aligns with the broader trend toward personalized healthcare, offering more targeted and efficient solutions for managing OIC. Personalized OIC treatments can optimize treatment plans, ensuring patients receive the most effective therapies for their specific condition. This can lead to improved symptom management and overall treatment efficacy, which will help new opportunities arise in the market.
Restraints/Challenges
- Safety Concerns Impacting OIC Drugs
The safety profile of opioid medications, including the potential for addiction and overdose, significantly influences the adoption and use of opioid-induced constipation (OIC) drugs. Healthcare providers and patients are often wary of using opioids due to these safety concerns, which can lead to hesitancy in prescribing and reluctance in seeking treatment and create challenges for the market.
- Stigma and Misconceptions
There is a stigma associated with opioid use, which can lead to misconceptions about the need for OIC drugs and reluctance among patients to seek treatment. This stigma can also impact healthcare provider attitudes and prescribing practices, affecting the uptake of OIC drugs and hindering market growth.
This opioid induced constipation drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the opioid induced constipation drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2022, Bausch Health Companies Inc. and its gastroenterology division, Salix Pharmaceuticals, announced research findings indicating that patients who received FDA-approved prescription medications for opioid-induced constipation (OIC-Rx), such as RELISTOR subcutaneous injection (SC) (methylnaltrexone bromide), in the emergency department (ED) were less likely to require hospitalization. Moreover, those who were hospitalized had shorter stays compared to patients who did not receive OIC-Rx in the ED. These results underscore the potential of RELISTOR SC to offer relief for individuals with OIC.
- In January 2022, BioGaia Pharma reported the enrollment of the first patient in a Phase II clinical study evaluating BGP345A for the treatment of opioid-induced constipation (OIC-1).
- In February 2021, Cosmo Pharmaceuticals revealed a partnership with RedHill Biopharma Ltd. for the production of Movantik, intended for the treatment of opioid-induced constipation (OIC) in adult patients.
Opioid Induced Constipation Drugs Market Scope
The opioid induced constipation drugs market is segmented on the basis of active ingredient, treatment, route of administration, distribution channel, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Active Ingredients
- Naloxegol
- Lubiprostone
- Methylnaltrexone Bromide
- Docusate Sodium
- Others
Treatment
- Over The Counter Medicines
- Prescription
- Natural Remedies
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Opioid Induced Constipation Drugs Market Regional Analysis/Insights
The opioid induced constipation drugs market is analyzed and market size insights and trends are provided by country, active ingredient, treatment, route of administration, distribution channel, and end-user as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America is expected to dominate the market due to the presence of major product manufacturers, which contributes to a robust market presence and availability of OIC drugs. The region is witnessing a significant increase in research and development efforts aimed at developing innovative treatments for OIC, further driving market growth. Substantial healthcare expenditure for addressing gastrointestinal disorders, including OIC, underscores the importance and demand for effective OIC drugs in the region.
Asia-Pacific is expected to witness significant growth due to the increase in new research and developments concerning opioid-induced constipation drugs. The region benefits from advanced healthcare infrastructure availability and earlier drug approvals for opioid-induced constipation drugs, courtesy of the accelerated drug approval initiative by the U.S. FDA, which is likely to propel market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The opioid induced constipation drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for opioid induced constipation drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the opioid induced constipation drugs market. The data is available for historic period 2011-2021.
Competitive Landscape and Opioid Induced Constipation Drugs Market Share Analysis
The opioid induced constipation drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Aurobindo Pharma (India)
- S.L.A. Pharma AG (U.K.)
- Salix Pharmaceuticals (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Abbott(U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Daewoong Pharmaceutical Company (South Korea)
- Cosmo Pharmaceuticals (Ireland)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
